SSR2 and hepatocellular carcinoma: To identify SSR2‐related signalling pathways in HCC, SSR2‐high and SSR2‐low expression data sets were enriched with the MSigDB Collection (h.all.v7.2.symbols.gmt, c6.all.v7.2.symbols.gmt, etc.)to reveal significant differences (false discovery rate [FDR] < 0.25 and p‐adjust <0.05).